Contextualizing ADC Integration in Breast Cancer Management

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have shifted the clinical management of various breast cancer subtypes.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates are weighed against other treatments in breast cancer care.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss emerging data for TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how the emergence of antibody-drug conjugates may impact sequencing considerations in triple-negative breast cancer.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss the role of antibody-drug conjugates in the management of hormone receptor–positive breast cancer.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have altered the HER2-positive breast cancer treatment paradigm.

Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, outline key future directions for antibody-drug conjugate (ADC) development in breast cancer.